Related references
Note: Only part of the references are listed.Radiation necrosis following treatment of high grade glioma-a review of the literature and current understanding
Alan Siu et al.
ACTA NEUROCHIRURGICA (2012)
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Preliminary experience with personalized and targeted therapy for pediatric brain tumors
Johannes E. Wolff et al.
PEDIATRIC BLOOD & CANCER (2012)
AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
O. L. Chinot et al.
ADVANCES IN THERAPY (2011)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim et al.
CANCER DISCOVERY (2011)
Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited
Nicola Montano et al.
NEOPLASIA (2011)
Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN
Ana Custodio et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2010)
Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?
Michael Weller et al.
FUTURE ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
Lucia Ricci-Vitiani et al.
NATURE (2010)
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J. Raizer et al.
NEURO-ONCOLOGY (2010)
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
W. K. Alfred Yung et al.
NEURO-ONCOLOGY (2010)
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sith Sathornsumetee et al.
NEURO-ONCOLOGY (2010)
Genetic alterations and signaling pathways in the evolution of gliomas
Hiroko Ohgaki et al.
CANCER SCIENCE (2009)
EGF receptor inhibitors in the treatment of glioblastoma multiform: Old clinical allies and newly emerging therapeutic concepts
Macoura Gadji et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
The EGFRvIII variant in glioblastoma multiforme
Hui K. Gan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Biology of Angiogenesis and Invasion in Glioma
Matthew C. Tate et al.
NEUROTHERAPEUTICS (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme
Roberto Pallini et al.
CLINICAL CANCER RESEARCH (2008)
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
J. F. de Groot et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Dieto Brandsma et al.
LANCET ONCOLOGY (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas
L. Doherty et al.
NEUROLOGY (2006)
Recent advances in the treatment of malignant astrocytoma
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma
MD Prados et al.
NEURO-ONCOLOGY (2006)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The natural history of EGFR and EGFRvIII in glioblastoma patients
AB Heimberger et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2005)
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Share Paper
